{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T12:40:09Z","timestamp":1736080809731,"version":"3.32.0"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T00:00:00Z","timestamp":1735948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T00:00:00Z","timestamp":1735948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-024-03716-4","type":"journal-article","created":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T22:12:57Z","timestamp":1736028777000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bridging the gap in early diagnosis of hidradenitis suppurativa"],"prefix":"10.1007","volume":"317","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-4701-6452","authenticated-orcid":false,"given":"Natalia V","family":"Chalupczak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie K","family":"Lovell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven R","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,4]]},"reference":[{"key":"3716_CR1","doi-asserted-by":"publisher","first-page":"990","DOI":"10.2340\/00015555-2176","volume":"95","author":"N Vlassova","year":"2015","unstructured":"Vlassova N, Kuhn D, Okoye GA (2015) Hidradenitis suppurativa disproportionately affects African americans: a single-center retrospective analysis. Acta Derm Venereol 95:990\u2013991","journal-title":"Acta Derm Venereol"},{"key":"3716_CR2","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/bjd.18983","volume":"184","author":"AV Marzano","year":"2021","unstructured":"Marzano AV, Genovese G, Casazza G et al (2021) Evidence for a window of opportunity in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study. Br J Dermatol 184:133\u2013140","journal-title":"Br J Dermatol"},{"key":"3716_CR3","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1159\/000508787","volume":"236","author":"G Kokolakis","year":"2020","unstructured":"Kokolakis G, Wolk K, Schneider-Burrus S et al (2020) Delayed diagnosis of Hidradenitis Suppurativa and its effect on patients and Healthcare System. Dermatology 236:421\u2013430","journal-title":"Dermatology"},{"key":"3716_CR4","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1001\/jamadermatol.2021.4926","volume":"158","author":"S Der Sarkissian","year":"2022","unstructured":"Der Sarkissian S, Hessam S, Kirby JS et al (2022) Identification of biomarkers and critical evaluation of biomarker validation in hidradenitis suppurativa: a systematic review: a systematic review. JAMA Dermatol 158:300\u2013313","journal-title":"JAMA Dermatol"},{"key":"3716_CR5","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s00403-021-02233-y","volume":"314","author":"PC Macklis","year":"2022","unstructured":"Macklis PC, Tyler K, Kaffenberger J et al (2022) Lifestyle modifications associated with symptom improvement in hidradenitis suppurativa patients. Arch Dermatol Res 314:293\u2013300","journal-title":"Arch Dermatol Res"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03716-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-03716-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03716-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T12:02:00Z","timestamp":1736078520000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-03716-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,4]]},"references-count":5,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3716"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-03716-4","relation":{},"ISSN":["1432-069X"],"issn-type":[{"type":"electronic","value":"1432-069X"}],"subject":[],"published":{"date-parts":[[2025,1,4]]},"assertion":[{"value":"6 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Steven R. Feldman has received research, speaking, and\/or consulting support from Eli Lilly and Company, GlaxoSmithKline\/Stiefel, AbbVie, Janssen, Alovtech, vTv Therapeutics, Bristol-Myers Squibb, Samsung, Pfizer, Boehringer Ingelheim, Amgen, Dermavant, Arcutis, Novartis, Novan, UCB, Helsinn, Sun Pharma, Almirall, Galderma, Leo Pharma, Mylan, Celgene, Ortho Dermatology, Menlo, Merck & Co, Qurient, Forte, Arena, Biocon, Accordant, Argenx, Sanofi, Regeneron, the National Biological Corporation, Caremark, Teladoc, BMS, Ono, Micreos, Eurofins, Informa, UpToDate, and the National Psoriasis Foundation. He is the founder and part owner of Causa Research and holds stock in Sensal Health. Natalia Chalupczak and Katie K. Lovell declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"168"}}